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Summary
We have studied two y/S T cell clones, E102 and E117, generated in a mixed lymphocyte culture
using an allogeneic Epstein-Barr virus-transformed B cell line, E418 . These clones were both
found to express a molecular form of T cell receptor (TCR) infrequent in human peripheral
blood, associating a V1-J1-C S chain and a V3-JP2-C2 y chain. Functionally, they appeared
as cytotoxic T lymphocytes (CTL) with non-major histocompatibility complex (MHC) (class
I and II) requiring cytotoxicity, able to kill both the immunizing (i.e., E418) and unrelated (e.g .,
K562, REX, F601, and KAS) target cells. A monoclonal antibody, anti-10H3, able to selectively
inhibit the cytotoxic activity of the clones has been produced . This reagent defines a 43-kD molecule,
designated TCT1, with broad distribution in the hematopoietic system, that appears to be distinct
from class IMHC gene products . A series offunctional experiments using various effector/target
cell combinations strongly suggested that TCT1 may represent a unique TCR ligand involved
in the interaction between these particular CTL clones and certain of the target cells tested,
while others were likely to be recognized and killed through a TCR-independent natural killer-like
pathway. Although further experimentation will be needed to strengthen our interpretation of
the present data, this study provides additional evidence that some T lymphocytes, in particular
of the y/S type, may interact specifically with target cells in a non-MHC class I/II-requiring fashion.
T
he molecular characterization of the human TCRy/b
has progressed very rapidly (1-10) . However, the physi-
ological contribution to immune responses of the minor T
lymphocyte fractions expressing this recognition structure
remains unclear. Multiple in vitro studies aimed at defining
the antigenic repertoire of they/STCR are being performed
that will eventually contribute to elucidate the biological func-
tions of the corresponding cells. It has been shown initially
that IIr2-dependent -ylb T lymphocytes may display a non-
MHC requiring cytotoxicity (11-14), suggesting their pos-
sible role in "immune surveillance" as effector lymphocytes
able to kill virally infected or tumor cells. Allogeneic -ylb
CTL recognizing either class I (15-18) or class II (19, 20;
F. Mami-Chouaib and T. Hercend unpublished data)MHC
gene products have also been identified in murine and human
systems. In addition, several reports have suggested that -ylb
lymphocytes may interact with target cells through recogni-
tion ofMHC class I-like molecules (reviewed in reference
21), such as TL (16), Qa1 (22), and CD1c (23, 24) . Other
specific responses, either conventionally MHC restricted or
not, have been described against various antigens such as
mycobacterias, heat-shock proteins, tetanus toxoid, and Igs
(25-33) . Together, these data have indicated thaty/S T lym-
phocytes can recognize a large variety of antigens while not
usingMHC class I or class II gene products as predominant
restriction elements like the a//3 counterparts .
With particular respect to CTL, the reported reactivities
(e.g., class I, class II, TL, and CD1c) have appeared to in-
volve very limited cell fractions within the y/S population
(16-20, 23, 24) . Thus, we have tried to further assess the
specificity ofhuman y/S T cells via the generation of alloreac-
tive cloned cell lines . We describe here two clones, E102 and
E117, generated in MLR against an EBVtransformed B cell
line, designated E418 . Both of these -ylb lymphocytes were
found to recognize and kill the E418-immunizing cells . A
43-kD surface molecule, termed T cell target 1 (TCT.1),t
broadly distributed in the hematopoietic system, was shown
to be recognized on the target cells in these unique cytotoxic
interactions.
1 Abbreviations used in this paper: LAK, lymphokine-activated killer ; TCT1,
T cell target 1 .
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Generation ofCloned CellLines.
￿
NonadherentPBMC were ob-
tained from a healthy individual using Ficoll-Hypaque (Pharmacia
Fine Chemicals, Uppsala, Sweden) density gradient centrifugation
followed by plastic adherences. CD3', TCR- ,y/6' lymphocytes
were purified by theimmuno-rosetting technique (immuno-deple-
tion), using anti-CD4 (OKT4), -CD8 (OKT8), -CD14 (MY4),
-CD20 (B4), -NKH1(N901), andBMA031 mAbs as described pre-
viously (19) . The CD3',TCRy/6'-enriched fraction was plated
on a feeder layer (104 cells/well) of irradiated EBVtransformed B
cell line (E418) in a U-bottomed 96-well plate at 2 x 104 cells/
well . Thecultured cells were restimulated weekly with irradiated
E418 cells, and rIIr2 was added every 3 d starting from day 12 .
Limiting dilution cloning of the cell line was performed in V
bottomed 96-well plates at 0.5 cells/well on a feeder layer containing
irradiated allogeneic PBL plus E418 cells (6 x 10' PBL + 4 x
10' E418/well) .
JT9 and AB12 (a//3 and y/b T cell clones, respectively) used
as controls were described previously (8, 34-37) . TheNK cell line
CD3- .1) has been developed from the CD3- PBL.
Previously Described mAbs and Phenotypic Analysis of the T Cell
Clones . AntiTiyA mAb (38) recognizes a Vy9-encoded epitope
and recognizes approximately two-thirds of humany/b PBL . Anti-
TCR-61, kindly provided byM.B. Brenner (Dana-Farber Institute,
Boston, MA), reacts with a constant determinant of the TCR 6
chain (39) . 6TCS1 mAb (40) reacts specifically with a structure
encoded by V61J61 gene products (37, 41) . A13 and TiV62 (42)
react with V61 and V62 gene products, respectively. BMA031,
kindly provided by Dr. R. Kurrle (Behring Company, Marburg,
FRG), reacts with a monomorphic determinant of theTCR-a/o
receptor . The anti-NKTa mAb recognizes an a//3 clonotypic de-
terminant (35) . OKT3, OKT4, and OKTS (Ortho Diagnostics
Systems Inc., Westwood, MA) react with CD3, CD4, and CD8
proteins, respectively. W6/32 (43) and 9-49 (44) mAbs recognize
nonpolymorphic determinants ofHLA class Iand class II gene prod-
ucts, respectively. B1.23.2 (anti-class I H chain) andB2.G2.2 (anti-
02microglobulin [02m]) were kindly provided by Dr. F . Lemonier
(Luminy, Marseille, France) . 2F3 (antiTNKTar) reacts with a
140-kD activation antigen described previously as a target struc-
ture for a series of human NKTa' T cell clones (45) . Each mAb
was used at a saturating concentration predetermined by titration
curves on positive cloned cell lines.
Phenotypic analysis of the cloned cell lines was carried out by
indirect immunofluorescence using an EpicsC flow cytometer as
described previously (34) . Allogeneic tissues were analyzed by a
radioisotope immunofiltration assay using disposable microfolds (V
& P Scientific, Inc.) . 104 cells/filter were incubated for 2 h at room
temperature, washed, and then 105 cpm of 'III-radiolabeled 1OH3,
W6/32, or irrelevant mAbwere added . After a2-h incubation and
three-step washing, radioactivity on the filter disks was counted
using a LKB gamma counter.
Generation ofthe IOH3 mAh
￿
12-wk-old Biozzi mice were im-
munized with E418 EBVtransformed B cells; 5 x 106 cells were
intraperitoneally injected in CFA followed by three intraperitoneal
injections of 5 x 106 cells emulsified in IFA at 2-wk intervals. 10 d
later, 5 x 10 6 cells were injected intravenously in PBS, and spleno-
cytes were fused after an additional 3 d to NS1 cells as previously
described (34) . Screening of the hybridomas was carried out by
inhibition of the E117 cytotoxicity against the E418 target cells.
Target Cells.
￿
The K562 (derived from a patient with chronic
myelogenous leukemia) and REX (a/a leukemia) cell lines were
used in NK assays . B cell lines, homozygous forHLA-DR antigens
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KAS 116 (DRI), E418 1324 (DR2), RSH (DR3),JHAF (DR4),
BM16 (DR5), Daudi (DRW6), MOU (DR7), MADURA
(DRW8), ARBO (DRW9), andF601 (DRW10), kindly provided
by Dr. J. Colombani (St . Louis Hospital, Paris), were used as targets
in cytotoxicity assays.
Cytotoxicity Assays.
￿
The cytotoxic activity of the cloned cell
lines was measured by a conventional 3-h "Cr-release assay using
triplicate cultures in V -bottomed plates. E/T ratios were 10:1, 3:1,
1:1, and 0.3 :1 on 5,000 target cells/well . Percent specific cytotox-
icity was calculated conventionally ; SD were <5%.
W6/32 (anti-class 1), 9-49 (anti-class II), OKT3, 6TCS1, as
well as 1OH3 mAbs were used in functional assays. The 2F3 mAb
(antiTNKTar)wasused as a control . Functional effects ofthe anti-
bodies, either on effector (OKT3, 6TCS1, 10113, and 2F3) or on
target (10113, W6/32, 9-49, and 2F3) cells, were tested by in-
cubating each of them for 2 h at 37°C before the assay at the
predetermined saturating concentration.
Immunoprecipitation of the TCR-y/6 and the TCT1 Molecule .
E102, E117, E418, and K562 cells were surface labeled with 1251
using a lactoperoxidase method as described previously (14, 38) .
Labeledcells were then lysed with phosphatebuffer containing1%
Triton X-100 (Sigma Chemical Co ., St . Louis, MO). The lysates
were precleared several times with Staphylococcus A suspension
and irrelevant mAbs before specific immunoprecipitation .
Immunoprecipitation of the TCR-y/b expressed by E102 and
E117 was carried out overnight at 4°Cby antiTCR-61 and -6TCS1
mAbs followed by protein A-Sepharose beads as described previ-
ously (42) . Immunoprecipitation of the TCT.1 molecule from the
E418 B cell line was performed using anti-10113 mAb coupled to
protein A beads . K562 cells were used as negative control . SDS-
PAGE analysis was carried out using 10% polyacrylamide gels ether
undernonreducing conditions or reducing conditions after adding
5% of 2-ME .
Southern Blot Analysis.
￿
High molecularweight genomicDNA
samples (10 hg) were digested either by EcoRI, BamHl, HindIIl,
or KpnI restriction enzymes, fractionated in 0.7% agarose gel, and
blotted on to Gene Screen Plus nylon membrane (46) . Hybridiza-
tion was carried out at 65°C in 6x SSC, 0.5% SDS, 5x Den-
hart's, 0.01 M EDTA, and 100 Etg/ml denatured salmon sperm
DNA. Blotswere washed twice at 65°C for30 min in 0.1 x SSC,
0.01% SDS . V61 (a 250-bp EcoRI-BamHI fragment cloned from
F6C7 cells) (37), pH60 (a 700-bp EcoRI-HindIII fragment con-
tainingJyl segment) (3), V-yI (a 1,100bp Sacl fragment containing
a Vy3 segment) (47), and VyIII (a 600-bp PstI-EcoRI fragment
containing aVy10 segment) (4) probes were labeled by the random
priming method using a-["P]dCTP (48) .
Results
Generation oftheE102 andEll7-ylb TCell Clones.
￿
PBMC
were extractedby Ficoll-Hypaque centrifugation, and adherent
cells were removedby two-steps adherence on plastic dishes.
The y/6T cells were purified by an immuno-rosetting tech-
nique (19) usingBMA031(antiTCRot/O), anti-CD4, anti-CD8,
anti-CD20 (B cell-specific), anti-CD14(monocytes-specific),
and anti-CD56/NKH1 (anti-N901) mAbs. Nonrosetting lym-
phocytes were cultured at 2 x 104 cells/well in the presence
of irradiated (104 cells/well) EBVtransformed B cells, termed
E418 . Further stimulations by E418 cells were performed
weekly over a4-mo period . rllr2 was addedevery3d, starting
from day 12 . The polyclonal cell line generated under theseconditions was found to display a stable CD3+, CD4- ,
￿
A
￿
B
CD8- , TCR61+, 6TCS1+, A13+, TiV62 - , and TiyA -
surface phenotype (data not shown) . Note here thatantiTCR
61 mAb is specific for a constant determinant of the TCR-6
chain (39), anti-BTCS1mAb for an epitope encoded by V61-
￿
NKTa
J61 (and/or possibly V61J62 ; see reference 49)-rearranged
gene segments (37), anti-A13 and antiTiV62 for peptides en-
coded by V61 andV62 gene segments, respectively (42), and
antiTiyA for the Vy9 gene product (38, 50) .
This cell line was then cloned by limiting dilution at 0.5
cells/well on a feeder layer containing both allogeneic PBh
and the sensitizing E418 B cell line . A series of clones with
cytolytic activity against the E418 cells were generated . Two
of them, termed E102 and E117, were studied in detail . Fig.
1 shows the reactivity of both clones with relevant mAbs .
In line with the phenotype of the originating cell line, they
were found to be CD3+, BMA031 - (TCR-oi/(3 '), TCR-
61+, STCS1+, A13+, TiV62 - , TiyA', CD4- . The NKH1
molecule was present on a fraction of the cells, as well as
￿
T1#A
CD8, which was expressed with very low density.
Together, this analysis indicated that the two clones posses
a Vy9 -/V61+ receptor, Such a TCR can only be found in
a very small y/6 peripheral cell fraction of the individual
studied here . Indeed, phenotypic analysis of hisPBL showed
￿
TcnM
that he had slightlymore than 5% circulating y/b lympho-
cytes with almost 5% TiyA+, 5% TiV62+ cells, and
<0.5% 6TCS1+ cells (data not shown) . More generally,
note that the STCS1 +/TiyA- phenotype corresponds to a
￿
drcs~
minority ofy/6 T cells in the peripheral blood of most adult
donors (8, 36, 51) .
Molecular Characterization ofthe TCR Expressed by E102 and
E117 T Cell Clones .
￿
A series of Southern blots were per-
formed to further characterize the organization ofthe TCR-y
￿
A'
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OKT3
and TCR-6 genes in the E102 and E117 clones . Large molec-
ular weight DNA from both cells was digested with either
EcoRI, BamHI, HindIII, or KpnI, fractionated on agarose
gel, blotted, and hybridized to a variety of relevant probes,
￿
Tivd:
Regarding the 6 chain rearrangements, Southern blot anal-
ysis of both clone DNAs with a V61 probe showed a 3-kb
EcoRI restriction fragment corresponding to the V61 germ-
line configuration, and a 3 .3-kb EcoRI band known to in
clude (5, 8) the Vb1-J61 rearrangement (data not shown) .
￿
NKH,
This result is in line with the surface reactivity of the anti-
6TCS1 mAb .
To assess the y chain rearrangements, we used the pH60
probe (a Jyl fragment), which hybridizes to both J-yl and
￿
OKT"
Jy2 gene segments (3) . There was no detectable rearrange-
ment when HindIII- and EcoRI-digested DNAs were hy-
bridized to this probe (data not shown), indicating that E102
and E117 do not use either the J-yl or the Jy2 gene segments
(4) . When DNAs were digested with the KpnI restriction
￿
OKTs
D
D
~__fj
enzyme, hybridizations with pH60 led to the detection of
the 16-kb Jy2 germline fragment plus two additional bands
at 4.7 and 8.5 kb (Fig. 2 A) . It has been previously shown
that such fragments correspond to rearrangements ofamember
￿
Figure 1 .
￿
Phenotypic analysis ofE102 (A) and E117 (B) -y/6 T cellclones
of either the V'y I or the V-yIII gene subfamily to JP2 and
￿
performed by indirect immunofluorescence experiments .
JP1, respectively (6) .1074
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Figure 2 .
￿
Southern blot analyses of
E102 and E117 y/S T cell clone
DNAs. DNA samples (10 lug) were
digested with EcoRI, HindIII,
BamHI, or KpnI restriction enzymes,
blotted, and hybridized with pH60
(A) or Vyl (B) probes. G corresponds
to germline DNA used as controls .Additional experiments were performed to define the ac-
tualV segments used by the clonedT cells. InBamHI digests,
the pH60 probe detected a rearranged band of>40 kb (Fig .
2 A) . Thus, is appeared likely that the V segments belong
to theVyI family, because the Vy10 (VyIII) rearrangements
to JP1 and JP2 are known to correspond to 26- and 22-kb
BamHI bands, respectively . This point was confirmed by the
hybridization of the EcoRI and the HindIII digests to the
VyIII probe (4) showing a deletion of this gene segment in
both E102 and E117 clones (data not shown) . Hybridizations
were then performed (Fig. 2 B) with a VyI probe including
the Vy3 segment (47) . After EcoRI digestion, this probe
detected in both clones a 5-kb rearranged fragment corre-
sponding to a Vy3JP2 recombination (6) . With HindIII,
one rearranged fragment was seen at 2.2 kb corresponding
to aVy8JP1 recombination . Digestion with BamHI led to
the detection of two rearranged bands at 19 and 47 kb corre-
sponding to the Vy3JP2 and the Vy8-JP1 recombinations,
respectively . The former was not detected clearly with Hin-
dIII, nor the latter with EcoRI, because the corresponding
rearranged fragments have approximately the same size as
germline bands present in the digests (i.e., 4.2 and 5.4 kb,
respectively) . Note that such rearrangements on both E102
and E117 chromosomes have led to the deletion of the 3.8-kb
EcoRI band (Fig. 2 B) corresponding to the germline form
of the Vy8 gene segment (4, 6) .
Together, these data indicated that the two clones have rear-
ranged the TCRy genes on both chromosomes. To identify
the productive rearrangement, we studied the quaternary struc-
ture of the receptor. Indeed, it is well known that the use
ofJP1 leads to the production ofdisulfide-linked y/6 dimers,
while the use ofJP2 results in the expression ofnon-disulfide-
linked receptors (2) . Immunoprecipitations performed with
the antiTCR61 and the anti-6TCS1 mAbs led to the detec-
tion oftwo bands at -48 and -42 kd in SDS-PAGE analysis
under nonreducing conditions (data not shown) .
In conclusion, these data, which are in line with the pheno-
typic analysis, strongly suggested that both E102 and E117
cells express a V61-J61-C6/Vy3JP2-Cy2 heterodimer. They
confirm that the cloned cell lines use a y/6 receptor with
a molecular structure infrequent in human peripheral blood .
Because both clones were found to display the same y and
6 chain rearrangements, they are likely to be derived from
the same cell. The complete sequence oftheirTCRy/6 chains,
particularly at the junctional regions, will have to be per-
formed in future studies to conclude on this point .
Functional Activity oftheE102 and E117y/6 T Cell Clones.
E102 and E117 cells were assayed for cytotoxic activity against
the E418-immunizing cells . The NK target cell line K562
was tested in parallel, as well as a panel of 10 EBVtransformed
and tumor B cell lines, including Daudi, which is known
for its susceptibility to lymphokine-activated killing. As shown
in Fig . 3, both clones displayed a high level of toxicity against
E418 . In contrast, there was little if any activity against the
Daudi target cell line. The cytotoxicity towards K562 varied
from one experiment to another, while being generally weaker
than that observed against E418 . Among theB cell lines tested,
only F601 and KAS (EBVtransformed B cells) were lysed
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by the two clones with a degree of efficiency (>15% lysis
at 10:1 E/T ratio), allowing further investigation (shown in
Fig . 4) .
To assess whether the recognition of E418 cellsby the clones
involves conventionalMHC molecules, we performed a se-
ries ofblocking experiments using anti-class I and anti-class
II antibodies. Neither W6/32 (anti-class I) nor 9-49 mAb
(anti-class II) were able to inhibit E102 or E117 cytotoxic
activity against E418 (Fig. 5, A-a and A-b) .
Together, these data indicated that E102 and E117 are T
lymphocytes with non-MHC class I/II-requiring cytotox-
icity, able to kill both the immunizing (i.e., E418) and un-
related (e.g ., K562, F601, and KAS) target cells.
Generation ofAnti-10H3, a mAb that Specifically Blocks E102
andE117 Cytotoxicity. To identify molecules potentially rec-
ognized by the clones, we attempted to develop mAbs able
to block their interaction with target cells . The E418 EBV
transformed B cell line was used to immunize 3-mo-old Bi-
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￿
Cytotoxic activity ofE102 (A) and E117 (B) .y/b T cell clones
against E418EBVtransformed B cell line (/), Daudi (+), and K562 (0)
target cells. E/T ratios were 10:1, 3 :1, 1:1, and 0 .3 :1 .Figure 4 .
￿
Cytotoxic activity of E102 (A) and E117 (B) T cell clones against E418 (a), F601 (b), KAS (c), and REX (d) target cells at 30:1, 10 :1,
3 :1, and 1 :1 E/T ratios. Cytotoxicity experiments were performed after target incubation either in media (/) or in the presence of the 1OH3 mAb (0) .
ozzi mice. Cell fusions were performed, and antibodies were
screened for their ability to alter the cytotoxicity of the E117
clone towards the E418 cells. Before testing the E117 lytic
activity, 51C-labeled target cells were thus treated for 2 h
with individual hybridoma supernatants. One hybridoma,
termed 10H3 (IgGl), with strong inhibitory effects was
selected for further analyses . Fig. 5, representative of mul-
tiple individual experiments, shows the virtual abrogation
of the cytotoxicity against E418 obtained with 10H3 mAb
using either E102 (A-a) or E117 (A-b) as effector cells .
Cellular Distribution and Characterization ofthe TCT1 Mole-
cule . The expression of the molecule, designated TCT1,
identified by the 10H3 mAb was assessed on both lymphoid
and nonlymphoid cells . In a first series of experiments, the
reactivity ofanti-10H3 was tested on the E418, Daudi, REX,
AB12, and K562 cell lines by indirect immunofluorescence
analysis (Fig. 6) . W6/32, B1.23.2 (anti-class I H chain),
B2.G2.2 (anti-02m), 9-49, B4 (anti-CD20), andOKT3 mAbs
were used as positive and negative control reagents. Except
for K562, all these cells were found to carry the TCT1 mole-
cule . The intensity ofexpression varied, however, among the
cell lines . Indeed, E418 (EBVtransformed B cell line) and
AB12 (I1,2-dependent T cell clone) cells displayed much higher
fluorescence density than Daudi (Burkitt lymphoma) andREX
(T cell leukemia) cells . Results obtained with the REX
(10H3+, W6/32+, B1.23.2+, B2.G2.2+, 9-49 - ) and the
Daudi cell lines (10H3+, W6/32 - , B1.23.2 - , B2.G2.2- ,
9-49+) are of particular interest because they suggest that
the TCT1 protein is distinct from the classical MHC class
I/II molecules and does not require the presence of the 02m
for its expression .
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More generally, resting PBL, monocytes, bone marrow cells,
EBVtransformed B cells (including F601 and KAS), cloned
T cell lines (including E102 and E117), and different leukemia
cell types were found to be positive. The reactivity of anti-
lOH3 on HL60, KGl (two myeloid cell lines), and polymor-
phonuclear cells was weak . Ramos (Burkitt lymphoma cell
line), U937 (histocytic cell line), and all the nonhematopoietic
normal and tumoral tissues tested, including liver, kidney,
breast, pancreas, placenta, colon, and ovary, were negative
(results summarized in Table 1) . All these cells were strongly
positive with the W6/32 reagent, confirming that TCT1
expression does not correlate with that of the conventional
class I molecules .
Immunoprecipitation experiments were performed with
1251-labeled E418 cells to define biochemically the TCT1
structure . As shown in Fig . 7, the anti-10H3 mAb precipi-
tated from the E418 cells a molecule resolving in SDS-PAGE
analysis as a unique 43-kD band under both reducing and
nonreducing conditions. The antiW6/32mAb tested in par-
allel, as a positive control reagent, immunoprecipitated from
the same cell lysate two bands at 43 and 12kD corresponding
to the class I H chain and to the02m, respectively (52) . Note
that the latter was not precipitated by the anti-10H3 mAb.
Because the TCT1 molecule resolved at a molecular mass
identical to that of the class I molecules, sequential im-
munoprecipitations were done using anti-10H3 and anti-
W6/32 . There were no crossalterations of the specific bands,
confirming that the two reagents recognize distinct proteins
(data not shown) . Control experiments included anti-10H3
immunoprecipitations from the 10H3 - K562 cells where no
signal was detected (data not shown) .B
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Specificity oftheAnti-10H3 ntAb Inhibitory Effects.
￿
Because
TCT 1 was found to be expressed by CTL themselves, ex-
periments were performed to assess whether the 10113 anti-
body inhibits cytotoxicity through interaction with the target
cell membrane. It was found that anti-10113 had no effect
at all regardless ofthe target tested (i .e., E418, F601, and KAS)
when incubated with E102 and E117 effector cells . In con-
trast, either treatment of target cells followed by subsequent
washing or direct addition of themAb in the microtiter wells
revealed constantly the biological activity (Fig. 8) .
In light of the broad distribution of the TCT1 molecule
in the hematopoietic system, we tested the blocking activity
of anti-10113 in E/T cell combinations distinct from E102
(or E117)/E418 . The selected killer cells included AB12 (a
y/6 T cell clone with the predominant peripheral TiyA+/
TiVS2+ phenotype [8, 36, 37]), JT9 (an a/(d T cell clone
defined through the expression of the NKTa clonotypic de-
terminant [34, 35]), and CD3- .1, a polyclonalNK (OKT3- ,
NKH1+) cell line . The 10113+ Daudi cells were used as a
target because of their known susceptibility to the three types
(i.e., ot/,(3, y/4 and NK cells) of effectors. As shown in Fig.
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￿
Cytotoxic activity of E102 (a), E117 (b), and CD3 - .1 NK cell line (c) towards E418 target (A) ; and that of AB12 (~, JT9 (e), and the
CD3 -.1 NK cells () towards Daudi target (B) . E/T ratios were 10 :1, 3 :1, 1 :1, and 0 .3 :1 . Cytolytic experiments were performed either in media (/)
or in the presence of mAbs . E418 and Daudi target cells were preincubated for 2 h with saturating concentrations of the 1OH3 ([:1), W6/32 (anti-class
1) (*), 9-49 (anti-class 11) (0), or 2F3 (antiTNKTar) (A) mAbs, and then effector cells were added .
5 B, anti-10H3 had no effect at all in the cytotoxic reactions.
Controls includedW6/32 and 9-49 antibodies that were also
inactive, while, as described previously (45), antiTNKtar
blocked specifically the cytotoxicity mediated by JT9 cells
(Fig . 5 B-e) . Note, in addition, that anti-10113 was unable
to inhibit the cytotoxicity mediated by the CD3' .1 NK
cells against the E418 cell line (Fig . 5 A-c) . The activity of
JT9 andAB12 against E418 was too weak to test the blocking
effect of anti-10113 in the corresponding combinations.
Together, these data strongly suggested that TCT1 is not
involved in a generally operating pathway of cell-cell interac-
tion . Further experiments were performed to assess whether
anti-10H3 would alter the cytotoxic interaction between ei-
ther E102 or E117 and all TCT1+-susceptible target cells.
Three cell lines F601, KAS (EBVtransformed B cells), and
REX (aT cell leukemia commonly used inNK assays), were
tested in addition to E418 . The representative experiment
presented in Fig . 4 shows that the activity of anti-10H3 was
variable from one target cell to another. The antibody virtu-
ally abrogated the cytotoxicity against F601; its effect was
moderate with KAS, while it was totally inactive withREX .
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￿
Immunofluorescence analysis of E418, Daudi (B cell lines), AB12 (y/S T cell clone), REX (a/,Q T cell line), and K562 cells with 1OH3,
W6/32, B1.23.2 (anti-class I H chain), B2.G2.2 (anti-02m), 9-49 (anti-class II), and B4 (anti-CD20) mAbs . Indirect immunofluorescence studies
were performed with saturating concentrations of each mAb and FITC-conjugated goat anti-mouse Ig serum .
Discussion
To further investigate the antigenic specificity ofy/Shuman
T lymphocytes, we have developed clones able to recognize
and kill an allogeneic EBVtransformed B cell line, termed
E418. Two of them (E102 and E117), displaying a strong cyto-
toxic activity against the E418-immunizing cells, were found
to express an infrequent y/S heterodimer encoded by the VS1-
JS1-CS- and the Vy3JP2-Cy2-rearranged genes .
The lytic activity of the E102 and E117 cells was tested
against a series of additional target cells, including a panel
ofeight EBVtransformedB cell lines carrying variousMHC
class I and class II gene products, as well as conventional
NK/lymphokine-activated killer (LAK) target cells (K562,
REX, and Daudi) . There was little ifany cytotoxicity against
six of the B cell lines, while two (F601 andKAS) were lysed
more efficiently . The Daudi LAK target cell was not killed,
and varying levels oflysis were found against K562 andREX .
The cytotoxicity ofboth clones against the E418 cell line has
not altered by either antiW6/32 (anti-class I) or 9-49
(anti-class II) mAbs . Therefore, E102 and E117 appeared to
display a non-MHC class I/II-requiring cytotoxic activity.
To further study target cell recognition by the E102 and
E117 clones, we have generated a mAb, termed anti-10H3,
initially selected for its ability to block their cytotoxic inter-
action with the E418-immunizing cells. The corresponding
antigen, designated TCT1, has been characterized as a 43-
kD molecule. It was found to be broadly distributed in the
hematopoietic system, while cells from various other origins
appeared to be negative . Results obtained with the Daudi
cell line indicated that the TCT1 protein does not require
the /32m for its expression, and is therefore distinct from the
class I-like surface antigens .
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Experiments performed with appropriate preincubation of
either effector or target cells with anti-10H3 indicated that
its inhibitory effect resulted from its binding to the mem-
brane of target cells. Further investigations showed that anti-
10H3 hadno blocking activitywhen a variety ofT and NK
cells distinct from E102 and E117 were used as effectors . In
addition to E418, the functional activity o£ anti-10H3 was
assessed against NK target cells (REX) and EBVtransformed
B cell lines (F601 and KAS), susceptible to the cytotoxic ac-
tivity ofE102 and E117 . It was found to strongly inhibit the
cytotoxicity against the F601 cells while being active, although
less efficient, against the KA cell line . In contrast, the anti-
body did not alter at all the interaction of E102 or E117 with
the REX cell line .
Together, the present results support the view that the E102
and E117 lymphocytes "see" the TCT1 molecule on the sur-
face of target cells. It is now generally agreed that CTL can
recognize and kill cells through either a TCR-dependent or
a TCR-independent pathway, the latter corresponding to the
so-called NK-like activity (53) . We have recently postulated
that this NK activity observed with CTL may represent an
evolutionary conserved function (53) . Such a conversion could
allow for a broader in situ spectrum of target cell interaction
at the effector step of the cytolytic reaction. It may thus con-
tribute to destroy transformed cells that have lost, through
mutations, the antigen that originally initiated the develop-
ment of the T cell response .
Our data clearly indicate that the E102 and E117 clones
display NK-like function . The variability of the activity found
against K562 and REX probably corresponds to the known
dependence of NK/LAK (i.e., IIr2-augmented TCR-
independent NK activity mediated by either NK or T cells)Table 1 .
￿
Screening of the Anti-10H3 mAB Reactivity and
its Comparison with that o,f the Anti-W6/32
Cells were analyzed by indirect immunofluorescence (A and B) or by radi-
oisotope assay on microfolds (C). Data are percentage of positive cells .
Numbers in parentheses correspond to fluorescence intensity mean .
" In vitro established tumor, viral-transformed cell lines, and cloned cyto-
toxic cells . B cells : E418, Daudi, Ramos . T cells : AB12, E117 (-y/6),
REX (ot/0) .
Nonlymphoid cell lines : K562, HL60, KG1, U937 .
LAL : acute lymphoblastic leukemia (two LAL were tested) .
LLC : chronic lymphoblastic leukemia (two LLC were tested).
LAM: acute myeloid leukemia (three LAM were tested) .
t Three normal individuals were tested .
s Normal and tumor tissues were tested. +, Radioactivity binding ra-
tio,B/BO (B-specific radioactivity fixation, BO=nonspecific radioactivity
fixation) >26% and <37% . ±, B/BO >6% and<18% . -, B/BO <3%.
lysis upon the effector cell status for IIr2-induced activation
(24, 34, 53-55) . The absence of cytotoxicity against theDaudi
cell line,which represents oneoftheconventional LAKtargets,
reflects theheterogeneity at theclonal level regarding the II,
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Figure 7.
￿
Immunoprecipitation of the class I and theTCT1 molecules
from E418 cell line by W6/32 (lanes aand c) and anti-IOH3 (lanes b and
d) mAbs, respectively. Immunoprecipitated material was analyzed on a
minigelby SDS-PAGE under nonreducing (NR) or reducing (R) conditions .
2-augmentedNK function . This phenomenon, which is still
poorly understood, has been documented extensively (24, 34,
53, 56) .
Therecognition of theTCT1 molecule may allow to dis-
tinguish theTCRdependentandtheTCRindependent target
cell recognition by the E102 and E117 lymphocytes . That
TCTA is likely to be recognized via the ,y/b heterodimer is
supportedby several observations: (a) it has to be mentioned
that the interaction between the clones and the E418 cells
are inhibited by antiTCR antibodies (data not shown) . It
is known, however, that such data may reflect the transduc-
tion of a negative signal in effector cellseven when theTCR
is not involved in target cell recognition (18, 24, 57); (b) the
blocking activity of the antibody is dependent upon the use
of unique effector CTL, named here E102 and E117 . This
implies that the latter cells carry either a unique determinant
within a polymorphic molecule (i.e., their TCR) or alterna-
tively express anovelmonomorphic receptor (i .e., anunknown
8:T RATIO
Figure 8.
￿
Cytotoxic activity of E102 T cell clone against E418 target
cells at 10:1, 3:1, 1:1, and0.3 :1 E/T ratios . Cytotoxicity experiments were
performed either in media (/), after incubation for 2 h in the microtiter
wells of E418 with the 10H3mAb before the assay (0), and after target
(*) or effector (0) cells treatment for2 h by the 1OH3 mAb followed
by subsequent washing .
A. Cells
and cell lines" Phenotype
W6/32
reactivity
1OH3
reactivity
E418 T3 -/9-49+/B4+ 90 (205) 90 (179)
Daudi T3 -/9-49+/B4+ 0 90 (105)
Ramos T3 -/9-49+/B4+ 96 (172) 14
REX T3+/9-49-/B4- 95 (162) 95 (113)
AB12 T3+/9-49+/B4 - 94 (185) 94 (192)
E117 T3+/ ND /B4- ND 97 (173)
HL60 T3 -/9-49 -/B4 - 96 (159) 40 (79)
KG1 T3-/9-49+/B4 - 93 (167) 75 (94)
U937 T3-/9-49+/B4 - 99 (193) 1
K562 T3-/9-49 -/B4 - 68 (88) 0
LAL (lannibe) T3 -/9-49+/B4+ 99 (216) 88 (87)
LLC (Hehas) T3+/9-49 -/B4- 99 (190) 99 (152)
LAM (Tanguy) ND/ ND /B4 - 90 (184) 3
B. Cell fractionst
PBL 97 (159) 93 (125)
Monocytes 98 (187) 89 (126)
Bone marrow 91 (189) 82 (139)
Polymorphonuclear 95 (127) 46 (75)
C. Allogeneic tissuess
Liver
Kidney
Ovary
Placenta
Pancreas
BreastTCT 1 ligand) with highly restricted cellular distribution that
would be functionally critical in cell-cell interaction (given
the virtual abrogation of cytotoxicity found with certain target
cells) ; (b) the blocking activity is dependent upon the use
of individual target cells . If the TCT.1/ligand systemwould
operate through a simple model of bimolecular interaction,
one would expect that the specific antibody alters the cyto-
toxic interactions of E102 and E117 cells against all TCT.1+
targets. The data obtained here, particularly in theREX assays,
where anti-10H3 has no effect at all, does not favor the latter
possibility. A more likely hypothesis is that REX cells are
recognized by a distinct mechanism than the EBVtransformed
B cell lines, namely in an NK-like TCR/TCT1-independent
fashion . In addition, the varying levels of functional inhibi-
tion obtained with the three B cell lines tested further sug-
gest the existence of a complex pathway of TCTI recogni-
tion . Future studies will have to assess more directly the
potential TCR/TCTA interaction and to establish whether
TCT1 may serve as a peptide-presenting structure . This will
require further experimentation, including extended correla-
tions between relevant TCR structures and TCT1 involve-
ment, characterization of theTCT.1 moleculeby gene cloning,
and peptide-dependent induction of target cell recognition .
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